S*BIO and Onyx Pharmaceuticals Announce Expanded Development Collaboration for JAK2 Inhibitors
06-May-2010 -
S*BIO Pte Ltd and Onyx Pharmaceuticals, Inc. announced the expansion of their development collaboration and option and license commercialization agreement for S*BIO’s novel JAK2 inhibitors, SB1518 and SB1578, also known as ONX 0803 and ONX 0805, respectively. The expanded agreement builds upon ...
autoimmune diseases
clinical trials
hematology
+5